Clinical trials: Thyroid Diseases
Graves Disease, Hyperthyroidism/Thyrotoxicosis
Evaluating an AI Tool for Detecting Thyrotoxic States
This observational study aims to evaluate the performance of a software-based medical device, Glandy HYPER, in detecting the thyrotoxic state in patients with hyperthyroidism.
- Trial name
- NCT07017907
- Testing
- Heart rate-based AI software for detecting thyrotoxicosis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- THYROSCOPE INC.
Thyroid Cancer
A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
This will be a Phase II, open label study to establish the effect of once-daily oral doses of ZD6474 100mg in subjects with locally advanced or metastatic hereditary medullary thyroid cancer in whom no standard therapeutic option…
- Trial name
- NCT00358956
- Testing
- ZD6474 (vandetanib)
- Where
- 9 sites in United States, Australia and 6 more
- Volunteers
- 19 people
- Sponsor
- Genzyme, a Sanofi Company
Solid Tumors
Study of SNH-118110 in Advanced Solid Tumors
This is a multicenter, open-label, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SNH-118110 administered orally.
- Trial name
- SNH-118110 (NCT07649200)
- Testing
- SNH-118110 Soft Capsules
- Where
- China
- Volunteers
- 240 people
- Sponsor
- ScinnoHub Pharmaceutical Co., Ltd.
Thyroid Nodules, Thyroid Abnormalities
A Novel Ultrasound Probe for Thyroid Imaging and Machine Learning
The objective of the THYMAL 01 pilot study is to evaluate the Sound Blade Imaging System in subjects with benign thyroid nodules undergoing standard-of-care ultrasound imaging.
- Trial name
- THYMAL 01 (NCT07488585)
- Testing
- Thyroid ultrasound
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sound Blade Medical Inc.
Diarrhea, Medullary Thyroid Cancer
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Diarrhea in patients with MTC (Medullary Thyroid Cancer) can be debilitating and, in some cases life threatening. Findings in such patients include volume depletion, renal insufficiency, and electrolyte disorders.
- Trial name
- NCT01739634
- Testing
- CASAD
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Salient Pharmaceuticals Incorporated
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
The primary objective of this study is to investigate the efficacy, safety, and tolerability of RV 001 (teprotumumab), a fully human anti-IGF1R antibody, administered q3W for 6 months, in comparison to placebo, in the treatment…
- Trial name
- NCT01868997
- Testing
- teprotumumab, normal saline
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 88 people
- Sponsor
- Amgen
Hypothyroidism
A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism
The North Star study is a multi-center, Phase 2, double-blind, randomized, parallel group clinical study to evaluate the safe and effective dose conversion from Levothyroxine to North Star therapy.
- Trial name
- NCT05712421
- Testing
- North Star, Levothyroxine
- Where
- 31 sites in United States
- Volunteers
- 303 people
- Sponsor
- Neuvosyn Laboratories, LLC
Congenital Hypothyroidism
Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)
This is a multi-center, prospective, parallel-group, open-label, randomized clinical study in one hundred and twenty-six (126) neonates and infants diagnosed with CH.
- Trial name
- NCT05228184
- Testing
- Tirosint®-SOL, Levothyroxine Sodium
- Where
- 10 sites in United States
- Volunteers
- 34 people
- Sponsor
- IBSA Institut Biochimique SA
Advanced Solid Tumor
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose escalation, safety, pharmacodynamic, and PK study of CDK-002 in subjects with advanced/metastatic, recurrent, injectable solid tumors, whose disease has progressed…
- Trial name
- NCT04592484
- Testing
- CDK-002
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Codiak BioSciences
Thyroid Eye Disease
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.
This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with…
- Trial name
- UplighTED (NCT06307626)
- Testing
- Efgartigimod PH20 SC
- Where
- 76 sites in United States, Austria and 16 more
- Volunteers
- 105 people
- Sponsor
- argenx
Thyroid Nodule
Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid
Thyroid nodules are among the common alterations of the thyroid. Depending on the detection method the prevalence is between 20% and 50%, whereas the incidence increases with improvement of ultrasonic technology.
- Trial name
- NCT03395925
- Testing
- Celon Pro Surge
- Where
- Germany
- Sponsor
- Olympus Surgical Technologies Europe
Subclinical Hypothyroidism
Dietary Intervention With Únicla Dairy Products (DANTIAN)
Dietary intervention with Únicla dairy products, naturally enriched with selenium and omega-3 fatty acids, may improve thyroid-stimulating hormone (TSH) levels in women with subclinical hypothyroidism
- Trial name
- DANTIAN (NCT05019118)
- Testing
- Experimental milk, Experimental yogur, Experimental fresh cheese
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Cooperativas Lacteas Unidas
Graves' Disease
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants…
- Trial name
- NCT07286006
- Testing
- IMVT-1402
- Where
- 131 sites in United States, Australia and 9 more
- Volunteers
- 372 people
- Sponsor
- Immunovant Sciences GmbH
Thyroid Neoplasms
Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
This is a Phase 2 study being conducted at multiple centers in the United States. Patients having thyroid cancer that has spread to other parts of the body (i.e., metastatic) are eligible to participate.
- Trial name
- NCT00094055
- Testing
- AG013736
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pfizer
Thyroid Cancer
Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
The purpose of this study is to determine the safety and efficacy of oral lenvatinib in participants with medullary thyroid cancer (MTC) or radioiodine (131 I)-refractory/resistant differentiated thyroid cancer (DTC)…
- Trial name
- NCT00784303
- Testing
- Lenvatinib (DTC Cohort), Lenvatinib (MTC Cohort)
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 117 people
- Sponsor
- Eisai Inc.
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Thyroid Eye Disease, Graves Orbitopathy
A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
Thyroid eye disease (TED) is a rare autoimmune, inflammatory disorder of the orbit and represents the most common extra-thyroidal manifestation of Graves' disease (GD).
- Trial name
- ORBIT (NCT04737330)
- Testing
- Secukinumab
- Where
- 5 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor, Cholangiocarcinoma
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors (solid tumor, BTC and…
- Conditions
- Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer
- Trial name
- NCT05253053
- Testing
- TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel
- Where
- 9 sites in China
- Volunteers
- 84 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Poorly Differentiated Thyroid Carcinoma
PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma
This is a prospective, multicenter, open label Phase II Clinical Trial. 30 advanced poorly differentiated thyroid carcinoma patients who were histopathologically confirmed inoperable were enrolled in this study.
- Trial name
- NCT03387943
- Testing
- PLD, Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.